drugset / Trial / NCT02714322
MYL-1401A Efficacy and Safety Comparability Study to Humira®
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To assess the equivalence of MYL-1401A to Humira® with regards to efficacy in subjects with moderate-to-severe chronic plaque psoriasis
Timeline
- Start
- 2015-06
- Primary completion
- 2016-05
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | MYL-1401A | Protein / enzyme biologic | 40 mg | Subcutaneous |